Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and safety of MD1003 in patients with primary multiple sclerosis (PPMS) or secondary multiple sclerosis (SPMS) in a real-world clinical centre

Next Previous
X
Search
Trial Profile

Effectiveness and safety of MD1003 in patients with primary multiple sclerosis (PPMS) or secondary multiple sclerosis (SPMS) in a real-world clinical centre

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 30 Oct 2018 New trial record
    • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 To date (May 2018), a total of 220 patients have received MD1003 as per results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top